Biogen shares are tanking because a 71% surge in profits just wasn't enough

Sometimes a 71% surge in profits is not enough.

Shares of Biogen fell by up to 5% in early trading after the biotech company announced first quarter results that missed on earnings and revenues.

The numbers: Net profit escalated to $US822.5 million, or $US3.49 per share, from $US480 million, or $US2.02 per share, a year earlier. Investors had expected $US3.59 a share, according to Bloomberg.

Excluding non-recurring items, Biogen earned $US3.82 per share, missing expectations of $US3.87.

Revenues rose about 20% to $US2.55 billion, missing the estimate of $US2.645 billion.

“In the first quarter, we continued to gain share in the MS [multiple sclerosis] market and we believe that our MS product portfolio is well positioned to provide patients the breadth of choices that they need,” said CEO George Scangos in the earnings statement.

Scangos also said sales of its major oral multiple sclerosis drug Tecfidera slowed, and its revenues fell 10% quarter-over-quarter.

Last month, the stock spiked 9% after it announced preliminary results for an Alzheimer’s disease treatment.

The stock is up neary 27% year-to-date, and 28% over the past 12 months.

Here’s a chart showing the stock’s plunge on Friday:

NOW WATCH: Watch these giant container ships collide near the Suez Canal

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at